These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 57124)

  • 1. A phase I study of 5-azacytidine (NSC-102816).
    Shnider BI; Baig M; Colsky J
    J Clin Pharmacol; 1976 Apr; 16(4):205-12. PubMed ID: 57124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days.
    Lomen PL; Baker LH; Neil GL; Samson MK
    Cancer Chemother Rep; 1975; 59(6):1123-6. PubMed ID: 56988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of fazarabine in refractory pediatric solid tumors. A Pediatric Oncology Group study.
    Bernstein ML; Whitehead VM; Grier H; Dubowy R; Land V; Devine S; Murphy S; Kung F
    Invest New Drugs; 1993 Nov; 11(4):309-12. PubMed ID: 7512539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of twice weekly 5-azacytidine (NSC-102816).
    Vogler WR; Arkun S; Velez-Garcia E
    Cancer Chemother Rep; 1974; 58(6):895-9. PubMed ID: 4141280
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
    Lomen PL; Khilanani P; Kessel D
    Neoplasma; 1980; 27(1):101-6. PubMed ID: 6154898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice weekly 5-azacytidine infusion in dissmeinated metastatic cancer: a phase II study.
    Vélez-Garcia E; Vogler WR; Bartolucci AA; Arkun SN
    Cancer Treat Rep; 1977 Dec; 61(9):1675-7. PubMed ID: 74283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
    Bellet RE; Catalano RB; Mastrangelo MJ; Berd D
    Med Pediatr Oncol; 1978; 4(1):11-5. PubMed ID: 75498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880).
    Curt GA; Kelley JA; Fine RL; Huguenin PN; Roth JS; Batist G; Jenkins J; Collins JM
    Cancer Res; 1985 Jul; 45(7):3359-63. PubMed ID: 2408749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816).
    Bellet RE; Mastrangelo MJ; Engstrom PF; Strawitz JG; Weiss AJ; Yarbro JW
    Cancer Chemother Rep; 1974; 58(2):217-22. PubMed ID: 4133839
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
    Surbone A; Ford H; Kelley JA; Ben-Baruch N; Thomas RV; Fine R; Cowan KH
    Cancer Res; 1990 Feb; 50(4):1220-5. PubMed ID: 1688736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.
    van Groeningen CJ; Leyva A; O'Brien AM; Gall HE; Pinedo HM
    Cancer Res; 1986 Sep; 46(9):4831-6. PubMed ID: 2425959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of 5-azacytidine in sarcomas of bone.
    Srinivasan U; Reaman GH; Poplack DG; Glaubiger DL; LeVine AS
    Am J Clin Oncol; 1982 Aug; 5(4):411-5. PubMed ID: 6180626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of 5-azacytidine in solid tumors.
    Weiss AJ; Metter GE; Nealon TF; Keanan JP; Ramirez G; Swaiminathan A; Fletcher WS; Moss SE; Manthei RW
    Cancer Treat Rep; 1977; 61(1):55-8. PubMed ID: 67894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer.
    Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Chemother Rep; 1972 Oct; 56(5):649-52. PubMed ID: 4119908
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I trial of a 72-h continuous-infusion schedule of fazarabine.
    Amato R; Ho D; Schmidt S; Krakoff IH; Raber M
    Cancer Chemother Pharmacol; 1992; 30(4):321-4. PubMed ID: 1379523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
    Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
    Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.
    Bailey H; Tutsch KD; Arzoomanian RZ; Tombes MB; Alberti D; Bruggink J; Wilding G
    Cancer Res; 1991 Feb; 51(4):1105-8. PubMed ID: 1705165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-azacytidine in acute leukemia.
    Saiki JH; McCredie KB; Vietti TJ; Hewlett JS; Morrison FS; Costanzi JJ; Stuckey WJ; Whitecar J; Hoogstraten B
    Cancer; 1978 Nov; 42(5):2111-4. PubMed ID: 82472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of 5-azacytidine in solid tumors.
    Quagliana JM; O'Bryan RM; Baker L; Gottlieb J; Morrison FS; Eyre HJ; Tucker WG; Costanzi J
    Cancer Treat Rep; 1977; 61(1):51-4. PubMed ID: 67893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.